What is the Sai Parenterals PB ratio (price to book value)?
Sai Parenterals' price-to-book (PB) ratio is 4.55 at the 29 October 2026 close: a market capitalisation of ₹2,234 crore divided by shareholders' equity (book value) of ₹491 crore on 31 March 2026. That is a book value of ₹111.08 per share against a share price of ₹505.70.
What is the Sai Parenterals net worth?
Sai Parenterals' net worth — shareholders' equity in its consolidated balance sheet — was ₹491 crore on 31 March 2026. Its market value is a different figure: a market capitalisation of ₹2,234 crore at the 29 October 2026 close.
What is the Sai Parenterals shareholding pattern?
On 30 September 2026, Sai Parenterals' shares were held by promoters 51.16%, foreign portfolio investors (FII/FPI) 2.85%, domestic institutions (DII) 7.84% (including mutual funds at 0.30%) and retail and other non-institutional investors 38.15%.
What is the Sai Parenterals market cap?
Sai Parenterals' market capitalisation was ₹2,234 crore at the 29 October 2026 close: 4.42 crore shares at ₹505.70 each.
Is Sai Parenterals debt free?
No. Sai Parenterals had borrowings of ₹319 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.65. Its cash and current investments were ₹417 crore, so it held net cash of ₹97.5 crore.
What is the Sai Parenterals promoter holding?
Promoters held 51.16% of Sai Parenterals on 30 September 2026, unchanged from the previous quarter, according to the shareholding pattern filed with NSE.
What is the Sai Parenterals debt to equity ratio?
Sai Parenterals' debt-to-equity ratio was 0.65 on 31 March 2026: borrowings of ₹319 crore against total equity of ₹495 crore.
What is the Sai Parenterals free cash flow?
In FY26, Sai Parenterals generated ₹93.1 crore of cash from operations and spent ₹65.5 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹27.6 crore.
What are the Sai Parenterals latest quarterly results?
Sai Parenterals' latest results are for Q1 FY27 (April–June 2026), filed on 11 August 2026: consolidated net profit ₹7.9 crore; revenue from operations ₹179 crore.
What is the Sai Parenterals book value per share?
Sai Parenterals' book value per share was ₹111.08 on 31 March 2026: shareholders' equity of ₹491 crore divided by the 4.42 crore shares in issue. The share price at the 29 October 2026 close was ₹505.70.
What is the Sai Parenterals revenue and profit in FY26?
In FY26 (April 2025–March 2026), Sai Parenterals' consolidated net profit was ₹14.3 crore, on revenue from operations of ₹381 crore.
How does Sai Parenterals compare with its peers?
On FY26 consolidated figures, against Indoco Remedies, Panacea Biotec and Hikal: Sai Parenterals' operating margin of 5.7% is the highest of the four (Indoco Remedies 0.8%, Panacea Biotec −5.9%, Hikal 3.3%; peer average −0.6%).
What is the Sai Parenterals EPS?
Sai Parenterals' basic earnings per share (EPS) were ₹4.36 in FY26.
When are the Sai Parenterals next results?
Sai Parenterals will announce its Q2 FY27 results (July–September 2026) on Sunday, 1 November 2026, the date of the board meeting it has notified to the exchanges.
Sai Parenterals vs Indoco Remedies: how do they compare?
In FY26, Sai Parenterals earned net profit of ₹14.3 crore on revenue of ₹381 crore, against ₹95.2 crore on ₹1,845 crore for Indoco Remedies. Sai Parenterals' operating margin was 5.7% (Indoco Remedies 0.8%). At the 29 October 2026 close, Sai Parenterals' market capitalisation was ₹2,234 crore against ₹1,934 crore for Indoco Remedies.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
